Evidence map›Paper›PMID 35808923›Full record

ArticleInternal medicine journal2022

Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience.

Phillip C Nguyen, Jenny Muirhead, Joanne Tan, Anna Kalff, Krystal Bergin, Patricia Walker, Andrew Spencer

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Phillip C NguyenDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.ORCID 0000-0003-4482-1014
Jenny MuirheadDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Joanne TanDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Anna KalffDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Krystal BerginDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Patricia WalkerDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Andrew SpencerDepartment of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.
Alfred Health · AUAustralian Centre for HIV and Hepatitis Virology Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of upfront non-myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high-risk multiple myeloma (HR-MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR-MM. Two-year progression-free survival was improved in the ASCT-NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT-NMA alloSCT can be considered as upfront therapy in HR-MM.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaDisease-Free SurvivalHumansTransplantation, Autologousallogeneichigh riskmultiple myelomatransplant

Identifiers

PMID35808923
PMCPMC9543527
OpenAlexW4284990005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.